XtalPi Unveils Kodexia, a Closed-Loop AI Platform for siRNA Discovery

PUBLISHER ARTICLE PREVIEW

From the original article

XtalPi Holdings Limited announced the debut of Kodexia on October 6, 2026, describing it as the industry’s first closed-loop small interfering RNA (siRNA) discovery platform to combine generative AI, first-principles-driven biological modeling, and automated experimentation, and simultaneously disclosed six proprietary therapeutic programs built on the platform.

The company presented Kodexia as the expansion of its technology into nucleic acid therapeutics. The release describes siRNA therapeutics as a modality that silences disease-driving genes upstream of protein production, offering potential for biological targets that conventional modalities struggle to address. It lists the development constraints the platform is intended to answer: fragmented sequence and modification design processes, restrictive patent barriers, inconsistent translation from cellular assays to animal models, and limitations in delivering such therapies beyond the liver.

To address those constraints, XtalPi said it developed siFormer, the proprietary architecture at the core of Kodexia. According to the company, siFormer integrates RNA interference mechanisms with nucleic acid chemistry principles and incorporates RNA thermodynamics and structural features relevant to strand loading, target accessibility, and silencing efficiency. XtalPi said these mechanistic constraints steer molecular generation toward biologically plausible designs rather than relying on sequence correlations alone.

Through this unified approach, the company said, Kodexia is built to let researchers systematically balance potency, in vivo translation, durability, off-target activity, safety, and patentability rather than optimizing single endpoints in isolation.